Cepheid
Company

Last deal

$63.8M

Amount

Grant

Stage

22.10.2021

Date

3

all rounds

$117.85M

Total amount

date founded

Financing round

General

About Company
Cepheid is a molecular diagnostics company that develops, manufactures, and markets molecular systems and tests for genetic-based diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1996

Number of employees

Company Type

For Profit

Last funding type

Grant

IPO status

Private

Description

The company's technology automates complex and time-consuming manual procedures, providing fast and accurate test results for infectious diseases and cancer. Cepheid's GeneXpert® systems and Xpert® tests offer on-demand testing for respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology, and human genetics. Their solutions deliver actionable results for institutions of any size, from central laboratories and hospitals to near-patient settings.
Contacts

Phone number

Social url

Similar Companies
1000
Biocartis

Biocartis

Biocartis is a molecular diagnostics company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Lausanne, Switzerland

total rounds

9

total raised

$338.83M

count Of Investments

2
AccuGenomics

AccuGenomics

AccuGenomics is a molecular diagnostics company that develops a unique spike-in control technology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Health Diagnostics

Location

Wilmington, NC, USA
Genetic Analysis

Genetic Analysis

Genetic Analysis AS is a company that specializes in molecular diagnostics of gut imbalances.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Health Diagnostics

Location

Oslo, Norway

total rounds

1

total raised

$2M
Asuragen

Asuragen

Asuragen is a fully integrated diagnostics company specializing in mRNA-based solutions for molecular oncology and early cancer detection.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Austin, TX, USA

total rounds

5

total raised

$80M
M&A Details
1

Transaction name

Acquired by

Danaher

announced date

06.09.2016

price

$4B

Financials

Funding Rounds
7
3

Number of Funding Rounds

$117.85M

Money Raised

Their latest funding was raised on 22.10.2021. Their latest investor Innogenetics. Their latest round Grant

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Biomedical Advanced Research and Development Authority (BARDA)

Biomedical Advanced Research and Development Authority (BARDA)

BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Medical, Biotechnology

Location

Washington Cir NW, Washington, DC, USA

count Of Investments

64

count Of Exists

2
Co-Investors
Investors
5
3

Number of lead investors

5

Number of investors

Investor 
Lead 
Round 
Partners 
Innogenetics

Innogenetics

Innogenetics NV is a biotechnology company that develops and markets diagnostic products for therapy management and patient health.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Ghent, Belgium

total rounds

1

total raised

$9.58M

count Of Investments

2

count Of Exists

2
Wheatley Partners

Wheatley Partners

Wheatley Partners is a private equity firm focused on technology-related companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Great Neck, NY, USA

count Of Investments

54

count Of Exists

25
Biomedical Advanced Research and Development Authority (BARDA)

Biomedical Advanced Research and Development Authority (BARDA)

BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Medical, Biotechnology

Location

Washington Cir NW, Washington, DC, USA

count Of Investments

64

count Of Exists

2
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Oncomark acquired by Cepheid

Oncomark acquired by Cepheid

acquirer

Cepheid
Cepheid

date

16.12.2021

type

Acquisition
Oncomark

Oncomark

OncoMark develops companion diagnostic tests to support cancer drug development and improve outcomes for cancer patients.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Health Diagnostics

Location

Dublin, Ireland

total rounds

3

total raised

$5.3M

People

Founders
3
Steve Young
Steve Young

Steve Young

Mr. Young is responsible for cofounding and developing the product vision for BAM Labs. In his previous role at Digeo, he served as Vice President of Hardware and Operations and responsible for innovation in engineering and manufacturing to drive the development of Digeo’s consumer products. Before Digeo, Mr. Young co-founded Cepheid, where, as lead engineering architect, he ran product development from inception through production. While at Cepheid, Mr. Young developed patented DNA analysis instruments to accurately and quickly diagnose dangerous diseases. Cepheid has become an invaluable biological agent detection system for the U.S. Government’s analysis of Anthrax and other biological warfare agents. In 2000, Mr. Young led Cepheid through a successful initial public offering. His pioneering work in the computer field led to the development of the groundbreaking PowerBook® Duo sub-notebook during his more than ten years at Apple Computer. While there, he managed a team of more than 100 professionals and was responsible for PowerBook Duo’s architecture, engineering and manufacturing. During his tenure, PowerBook won numerous accolades, including Business Week’s prestigious Product of the Year award. Mr. Young also spent six years at the Robotics Institute at Carnegie Mellon University, where he secured his first patents as a research design engineer. He holds more than 30 patents for advanced electronics systems, DNA analysis techniques, robotic hands and other technologies. Mr. Young holds a B.S. in Electrical Engineering from Carnegie Mellon University.

current job

UDP Labs
UDP Labs

organization founded

3

Steve Young

Dennis H. Giesing
Dennis H. Giesing

Dennis H. Giesing

For over 30 years, Dr. Giesing has served in a variety of senior scientific and leadership roles within large pharmaceutical companies, with the last appointment being Senior Vice President, Lead Optimization at Aventis Pharmaceuticals, Inc. Prior to joining TARIS, Dr. Giesing served as Chief Scientific Officer for Urigen Pharmaceuticals. Earlier pharma positions include Vice President, Global Drug Metabolism & Pharmacokinetics at Aventis, as well as other leadership roles at Hoechst Marion Roussel, Marion Merrell Dow and Marion Laboratories. He earned a B.S. in Chemistry and his Ph.D. in Biochemical Pharmacology from the University of Missouri, Kansas City.

current job

TARIS Biomedical
TARIS Biomedical

organization founded

1

Dennis H. Giesing

Allen Northrup
Allen Northrup

Allen Northrup

Co-founder, CTO, VP Research at Cepheid.

current job

MIODx
MIODx

organization founded

1

Allen Northrup

Employee Profiles
341

Alisa Gee

Global senior ehs programs manager

Ms-Cls Vera Winn

Field application specialist

Gizelle Amador

Production manager

Andrew Noel

Territory sales executive

Paul Vo

Territory sales executive

Bob Bliss

Senior director global demand planning

Roya Kazemi

Quality system specialist

Linh Pham

Finance manager - revenue

Activity

Recent News
4
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month